ESLAW Company Profile and Key Details

Estrella Immunopharma, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by -44.44%. The prior quarter beat by -40.48%. Over the last six quarters, Apple has recorded several small beats. These include 119.03% in August 11, 2025.

Estrella Immunopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.04. This means the shares are trading above this model’s fair value.

The stock is currently within 5% of its 52-week low $0.07 and $0.11. With a market capitalization of about $24.57 million, Estrella Immunopharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.09). Key stats such as the average daily volume over the past year has been around 6.36 thousand shares, volume is running light vs its 52-week average. Headquartered in EmeryVille, CA, Estrella Immunopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Cheng Liu, the company employs approximately 3 people and listed since October 02, 2023. Estrella Immunopharma, Inc. is an early-stage biopharmaceutical firm based in Emeryville, California, dedicated to advancing T-cell immunotherapies for various hematological malignancies and solid tumors within the United States.

Valuation shows Estrella Immunopharma, Inc. trading at a premium to the broader market with a P/E of -2.73.

Our AI price prediction model suggests that Estrella Immunopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Estrella Immunopharma, Inc. trades at a P/E ratio of -2.73, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -3.89 indicating negative book value, which may reflect financial stress. The P/FCF stands at -3.06, also below market averages.